The concentration required to produce half-maximal growth inhibition, IC50, in FLT3-expressing AML cells through DBPR114 introduction was tenfold greater than that of the two known AURK inhibitors VX680 and barasertib [26]. The gene discussed is FLT3; the disease is acute myeloid leukemia.